Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOU064 in uncontrolled asthma (phase 2a)
CTR20200089Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of remibrutinib in asthma, sponsored by Novartis. Started Jan 2020; status: terminated.
02
Drugs
remibrutinib
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20200089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200089.